Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Leucogen for Preventing Ribociclib-Associated Neutropenia in Early Breast Cancer
NCT07380646Phase 2Recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Jan 2026
- Primary completion
- Jan 2028
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Leucogen in neutropenia, sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoint: Incidence of Severe Neutropenia (Grade 3 or higher) at 16 weeks. Started Jan 2026; status: recruiting.
02
Drugs
Leucogen
03
Conditions
neutropenia
Beyond the preview
Go deeper on NCT07380646.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07380646.